Cargando…

The Impact of SARS-CoV-2 Pandemic Lockdown on a Botulinum Toxin Outpatient Clinic in Germany

Botulinum neurotoxin type A (BoNT/A) injections have to be administered repeatedly to achieve a rather stable, high level of improvement. This study aimed to take a look at changes in the daily routine of a BoNT/A outpatient clinic due to the SARS-CoV-2 pandemic lockdown, analyze the impact of SARS-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Samadzadeh, Sara, Brauns, Raphaela, Rosenthal, Dietmar, Hefter, Harald
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7912331/ https://www.ncbi.nlm.nih.gov/pubmed/33573065 http://dx.doi.org/10.3390/toxins13020101

Ejemplares similares

The Extreme Ends of the Treatment Response Spectrum to Botulinum Toxin in Cervical Dystonia
por: Samadzadeh, Sara, et al.
Publicado: (2020)

The complex relationship between antibody titers and clinical outcome in botulinum toxin type A long-term treated patients with cervical dystonia
por: Hefter, Harald, et al.
Publicado: (2022)

Lessons about Botulinum Toxin A Therapy from Cervical Dystonia Patients Drawing the Course of Disease: A Pilot Study
por: Hefter, Harald, et al.
Publicado: (2023)

“Pseudo”-Secondary Treatment Failure Explained via Disease Progression and Effective Botulinum Toxin Therapy: A Pilot Simulation Study
por: Hefter, Harald, et al.
Publicado: (2023)

Clinical Implications of Difference in Antigenicity of Different Botulinum Neurotoxin Type A Preparations: Clinical Take-Home Messages from Our Research Pool and Literature
por: Samadzadeh, Sara, et al.
Publicado: (2020)

Comparing soleus injections and gastrocnemius injections of botulinum toxin for treating adult spastic foot drop: a monocentric observational study
por: Hefter, Harald, et al.
Publicado: (2021)

Enhanced Effect of Botulinum Toxin A Injections into the Extensor Digitorum Brevis Muscle after Local Mechanical Leg Vibration: A Case Report
por: Hefter, Harald, et al.
Publicado: (2021)

The Impact of the Course of Disease before Botulinum Toxin Therapy on the Course of Treatment and Long-Term Outcome in Cervical Dystonia
por: Hefter, Harald, et al.
Publicado: (2021)

Continuous Increase of Efficacy under Repetitive Injections of Botulinum Toxin Type/A beyond the First Treatment for Adult Spastic Foot Drop
por: Hefter, Harald, et al.
Publicado: (2021)

No Secondary Treatment Failure during Incobotulinumtoxin—A Long-Term Treatment Demonstrated by the Drawing of Disease Severity
por: Hefter, Harald, et al.
Publicado: (2023)

Significant Long-Lasting Improvement after Switch to Incobotulinum Toxin in Cervical Dystonia Patients with Secondary Treatment Failure
por: Hefter, Harald, et al.
Publicado: (2022)

The Use of High Initial Doses of Botulinum Toxin Therapy for Cervical Dystonia Is a Risk Factor for Neutralizing Antibody Formation—A Monocentric Cross-Sectional Pilot Study
por: Hefter, Harald, et al.
Publicado: (2022)

The Necessity of a Locally Active Antidote in the Clinical Practice of Botulinum Neurotoxin Therapy: Short Communication
por: Hefter, Harald, et al.
Publicado: (2022)

The impact of the initial severity on later outcome: retrospective analysis of a large cohort of botulinum toxin naïve patients with idiopathic cervical dystonia
por: Hefter, Harald, et al.
Publicado: (2020)

Effective Treatment of Neurological Symptoms with Normal Doses of Botulinum Neurotoxin in Wilson’s Disease: Six Cases and Literature Review
por: Hefter, Harald, et al.
Publicado: (2021)

Clinical Improvement After Treatment With IncobotulinumtoxinA (XEOMIN®) in Patients With Cervical Dystonia Resistant to Botulinum Toxin Preparations Containing Complexing Proteins
por: Hefter, Harald, et al.
Publicado: (2021)

Effective long-term treatment with incobotulinumtoxin (Xeomin®) without neutralizing antibody induction: a monocentric, cross-sectional study
por: Hefter, Harald, et al.
Publicado: (2020)

Disease Progression of Idiopathic Cervical Dystonia in Spite of Improvement After Botulinum Toxin Therapy
por: Hefter, Harald, et al.
Publicado: (2020)

Significantly lower antigenicity of incobotulinumtoxin than abo- or onabotulinumtoxin
por: Hefter, Harald, et al.
Publicado: (2022)

Exploring the Interplay between the Clinical and Presumed Effect of Botulinum Injections for Cervical Dystonia: A Pilot Study
por: Hefter, Harald, et al.
Publicado: (2023)

Very early reduction in efficacy of botulinum toxin therapy for cervical dystonia in patients with subsequent secondary treatment failure: a retrospective analysis
por: Hefter, Harald, et al.
Publicado: (2013)

Clinical relevance of neutralizing antibodies in botulinum toxin long-term treated still-responding patients with cervical dystonia
por: Hefter, Harald, et al.
Publicado: (2019)

Mildly Impaired Foot Control in Long-Term Treated Patients with Wilson’s Disease
por: Samadzadeh, Sara, et al.
Publicado: (2021)

Analysis of Running in Wilson’s Disease
por: Samadzadeh, Sara, et al.
Publicado: (2022)

Analysis of Single-Leg Hopping in Long-Term Treated Patients with Neurological Wilson’s Disease: A Controlled Pilot Study
por: Hefter, Harald, et al.
Publicado: (2022)

Long‐term adherence and response to botulinum toxin in different indications
por: Lee, John‐Ih, et al.
Publicado: (2020)

Cholinesterase Deficiency Syndrome—A Pitfall in the Use of Butyrylcholinesterase as a Biomarker for Wilson’s Disease
por: Arslan, Max, et al.
Publicado: (2022)

A botulinum toxin A treatment algorithm for de novo management of torticollis and laterocollis
por: Hefter, Harald, et al.
Publicado: (2011)

Rating scales for cervical dystonia: a critical evaluation of tools for outcome assessment of botulinum toxin therapy
por: Jost, Wolfgang H., et al.
Publicado: (2012)

Transient Improvement after Switch to Low Doses of RimabotulinumtoxinB in Patients Resistant to AbobotulinumtoxinA
por: Hefter, Harald, et al.
Publicado: (2020)

Pseudocholinesterase as a Biomarker for Untreated Wilson’s Disease
por: Hefter, Harald, et al.
Publicado: (2022)

Differences in the Time Course of Recovery from Brain and Liver Dysfunction in Conventional Long-Term Treatment of Wilson Disease
por: Hefter, Harald, et al.
Publicado: (2023)

Botulinum Toxin Services for Neurorehabiliation: Recommendations for Challenges and Opportunities during the COVID-19 Pandemic
por: Bavikatte, Ganesh, et al.
Publicado: (2021)

Different Response Behavior to Therapeutic Approaches in Homozygotic Wilson’s Disease Twins with Clinical Phenotypic Variability: Case Report and Literature Review
por: Samadzadeh, Sara, et al.
Publicado: (2022)

Botulinum toxin therapy in the SARS-CoV-2 pandemic: patient perceptions from a German cohort
por: Dressler, Dirk, et al.
Publicado: (2020)

BOTULINUM TOXIN
por: Nigam, P K, et al.
Publicado: (2010)

Botulinum toxin in the management of acquired motor fusion deficiency
por: Murthy, Ramesh, et al.
Publicado: (2009)

Why Do Females Use Botulinum Toxin Injections?
por: Singh, Carter, et al.
Publicado: (2015)

Altered cortical activation from the hand after facial botulinum toxin treatment
por: Haenzi, Sara, et al.
Publicado: (2014)

Botulinum toxin treatment for hypersalivation in anti‐NMDA receptor encephalitis
por: Jun, Jin‐Sun, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_oiggaal6fh2cle2rvv13uqseka